STAT+: Pharmalittle: We’re Reading About Medicare and Alzheimer’s Drugs, Estrogen Patch Shortages, and More

Why It Matters

The muted uptake undermines Medicare’s budgeting for high‑cost specialty drugs and questions the value proposition of expensive Alzheimer’s treatments, while the estrogen patch scarcity exposes a disconnect between market demand and regulatory reporting that could affect women’s health care continuity.

Key Takeaways

• Medicare uptake of Leqembi and Kisunla far below projections
• Expected billions in annual spending on Leqembi now unlikely for 2026‑27
• Intravenous administration and limited patient pool hinder Alzheimer drug adoption
• FDA hasn't listed estrogen patches as shortages despite pharmacist reports

Pulse Analysis

The underperformance of Leqembi and Kisunla highlights a growing tension between pharmaceutical innovation and real‑world utilization. Both drugs received accelerated FDA approval and were touted as breakthrough therapies for early‑stage Alzheimer’s, yet their intravenous administration, costly imaging protocols, and limited efficacy have deterred physicians and patients. Medicare’s revised spending outlook—shifting from projected billions to negligible outlays—signals that payers are re‑evaluating the cost‑benefit calculus of high‑price biologics, prompting biotech firms to reconsider pricing strategies and pipeline priorities.

At the same time, estrogen patches have entered a de‑facto shortage despite the FDA’s omission from its official shortage list. The removal of the black‑box warning on hormone‑replacement therapies spurred a surge in demand, outpacing manufacturers’ capacity to meet market needs. Pharmacists report 14 brands or dosages in short supply, forcing clinicians to seek alternative delivery methods or lower‑dose formulations. This gap between supply chain realities and regulatory visibility raises concerns for women reliant on consistent hormone therapy, especially as interruptions can exacerbate menopausal symptoms and long‑term health risks.

Both stories underscore systemic challenges in the U.S. drug ecosystem: innovative treatments often stumble on practical delivery hurdles, while supply‑demand mismatches can slip through regulatory monitoring. For policymakers, the lesson is clear—robust forecasting tools and transparent shortage reporting are essential to align patient access with commercial expectations. Health systems must also develop contingency plans, such as diversified formularies and patient education, to mitigate the impact of abrupt drug availability shifts.